Literature DB >> 3392654

Demonstration of the antihypertensive activity of phenyl-2-aminoethyl selenide.

S H Pollock1, H H Herman, L C Fowler, A S Edwards, C O Evans, S W May.   

Abstract

The effect of phenyl-2-aminoethyl selenide (PAESe) on blood pressure and heart rate was examined in anesthetized dogs and spontaneously hypertensive rats (SHR) in order to assess its possible utility as an antihypertensive agent. PAESe was shown to be an indirect-acting sympathomimetic whose transient increase in blood pressure was blocked by cocaine. PAESe exhibited potent antihypertensive activity in SHR. This hypotensive activity was dose-dependent, was evident in both acute and chronic assays and occurred after i.v. or i.p. administration or slow release from subdermally implanted osmotic pumps. The hypotensive activity in SHR occurred concomitant with a reduction in heart rate and a reduction in total body weight. Hearts isolated from SHR treated daily for 2 weeks with PAESe were significantly reduced in weight and in total catecholamine content. An investigation of the nature of the body weight loss which accompanied chronic dosing suggested that PAESe also possessed an anorexigenic property distinct from its antihypertensive activity. An examination of plasma electrolytes, enzymes and other metabolites from chronically treated rats showed no obvious toxic effects of such dosing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392654

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Toward pyridine-fused selenium-containing antioxidants.

Authors:  Tahli Fenner; Carl H Schiesser
Journal:  Molecules       Date:  2004-05-31       Impact factor: 4.411

Review 2.  Selenium-based antihypertensives. Rationale and potential.

Authors:  S W May; S H Pollock
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

3.  The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin.

Authors:  Xiaoyu Fu; Mathew Eggert; Sieun Yoo; Nikhil Patel; Juming Zhong; Ian Steinke; Manoj Govindarajulu; Emine Akyuz Turumtay; Shravanthi Mouli; Peter Panizzi; Ronald Beyers; Thomas Denney; Robert Arnold; Rajesh H Amin
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.